Bevacizumab in Japanese patients with malignant glioma: From basic research to clinical trial

OncoTargets and Therapy

Volumn 7, Issue , 2014, Pages 1551-1562

  Takano, Shingo ^a   Ishikawa, Eiichi ^a   Nakai, Kei ^a   Matsuda, Masahide ^a   Masumoto, Tomohiko ^a   Yamamoto, Tetsuya ^a   Matsumura, Akira ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Angiogenesis; Bevacizumab; Brain tumor; Clinical trial; Japanese; VEGF antibody

Indexed keywords

BEVACIZUMAB; NIMUSTINE; PLACEBO; TEMOZOLOMIDE; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CANCER SURVIVAL; CELL PROLIFERATION; CHEMORADIOTHERAPY; CLINICAL TRIAL (TOPIC); CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG TOLERABILITY; GLIOBLASTOMA; GROWTH INHIBITION; HUMAN; HYPERTENSION; IMMUNOLOCALIZATION; INTRATUMORAL BLEEDING,; JAPANESE (PEOPLE); NONHUMAN; OVERALL SURVIVAL; PATHOGENESIS; PHARMACOLOGICAL BLOCKING; PHASE 2 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEINURIA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME; TREATMENT DURATION; TUMOR GROWTH; TUMOR VOLUME; VENOUS THROMBOEMBOLISM;

EID: 84907200246     PISSN: 11786930     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S67621     Document Type: Article

References (26)

1. Norden AD, Drappatz J, Wen PY. Novel anti-angiogenic therapies for malignant gliomas. Lancet Neurol. 2008;7(12):1152–1160.
2. Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):709–722.
3. Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):699–708.
4. Takano S, Yoshii Y, Kondo S, et al. Concentration of vascular endothe-lial growth factor in the serum and tumor tissue of brain tumor patients. Cancer Res. 1996;56(9):2185–2190.
5. Takano S, Kamiyama H, Tsuboi K, Matsumara A, Nose T. Angiogenesis and antiangiogenic therapy for malignant gliomas. Brain Tumor Pathol. 2004;21(2):69–73.
6. Takano S, Tsuboi K, Matsumura A, Nose T. Anti-vascular endothelial growth factor antibody and nimustine as combined therapy: effects on tumor growth and angiogenesis in human glioblastoma xenografts. Neuro Oncol. 2003;5(1):1–7.
7. Knizetova P, Ehrmann J, Hlobilkova A, et al. Autocrine regulation of glioblastoma cell cycle progression, viability and radioresis-tance through the VEGF-VEGFR2 (KDR) interplay. Cell Cycle. 2008;7(16):2553–2561.
8. Hamerlik P, Lathia JD, Rasmussen R, et al. Autocrine VEGF-VEGFR2-Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth. J Exp Med. 2012;209(3):507–520.
9. Kamiyama H, Takano S, Tsuboi K, Matsumura A. Anti-angiogenic effects of SN38 (active metabolite of irinotecan): inhibition of hypoxia-inducible factor 1 alpha (HIF-1alpha)/vascular endothelial growth factor (VEGF) expression of glioma and growth of endothelial cells. J Cancer Res Clin Oncol. 2005;131(4):205–213.
10. Yang Y, Zhang Y, Cao Z, et al. Anti-VEGF- and anti-VEGF receptor-induced vascular alteration in mouse healthy tissues. Proc Natl Acad Sci U S A. 2013;110(29):12018–12023.
11. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevaci-zumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009;27(5):740–745.
12. Lai A, Filka E, McGibbon B, et al. Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. Int J Radiat Oncol Biol Phys. 2008;71(5):1372–1380.
13. Narayana A, Kelly P, Golfnos J, et al. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. J Neurosurg. 2009;110(1):173–180.
14. Norden AD, Young GS, Setayesh K, et al. Bevacizumab for recurrent malignant gliomas: effcacy, toxicity, and patterns of recurrence. Neurology. 2008;70(10):779–787.
15. Nagane M, Nishikawa R, Narita Y, et al. Phase II study of single-agent bevacizumab in Japanese patients with recurrent malignant glioma. Jpn J Clin Oncol. 2012;42(10):887–895.
16. Takano S, Kimu H, Tsuda K, et al. Decrease in the apparent diffusion coeffcient in peritumoral edema for the assessment of recurrent glioblastoma treated by bevacizumab. Acta Neurochir Suppl. 2013;118:185–189.
17. Takano S. Glioblastoma angiogenesis: VEGF resistance solutions and new strategies based on molecular mechanisms of tumor vessel formation. Brain Tumor Pathol. 2012;29(2):73–86.
18. Takano S, Mashiko R, Osuka S, Ishikawa E, Ohneda O, Matsumura A. Detection of failure of bevacizumab treatment for malignant glioma based on urinary matrix metalloproteinase activity. Brain Tumor Pathol. 2010;27(2):89–94.
19. Inoue S, Ichikawa T, Kurozumi K et al. Novel animal glioma models that separately exhibit two different invasive and angiogenic phenotypes of human glioblastomas. World Neurosurg. 2012;78(6):670–682.
20. McCarty JH. Glioblastoma resistance to anti-VEGF therapy: has the challenge been MET? Clin Cancer Res. 2013;19(7):1631–1633.
21. Tabouret E, Boudouresque F, Barrie M, et al. Association of matrix metalloproteinase 2 plasma level with response and survival in patients treated with bevacizumab for recurrent high-grade glioma. Neuro Oncol. 2014;16(3):392–399.
22. Fine HA. Bevacizumab in glioblastoma – still much to learn. N Engl J Med. 2014;370(8):764–765.
23. Lombardi G, Zustovich F, Farina P, et al. Hypertension as a biomarker in patients with recurrent glioblastoma treated with antiangiogenic drugs: a single-center experience and a critical review of the literature. Anticancer Drugs. 2013;24(1):90–97.
24. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27(28):4733–4740.
25. Chauffert B, Feuvret L, Bonnetain F, et al. Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF. Ann Oncol. 2014;25(7):1442–1447.
26. Holdhoff M, Chamberlain MC. Controversies in the treatment of elderly patients with newly diagnosed glioblastoma. J Natl Compr Canc Netw. 2013;11(9):1165–1172; quiz 1173.